keyword
https://read.qxmd.com/read/37926796/mindfulness-meditation-and-psychedelics-potential-synergies-and-commonalities
#21
REVIEW
Paweł Holas, Justyna Kamińska
There has been increasing scientific and clinical interest in studying psychedelic and meditation-based interventions in recent years, both in the context of improving mental health and as tools for understanding the mind. Several authors suggest neurophysiological and phenomenological parallels and overlaps between psychedelic and meditative states and suggest synergistic effects of both methods. Both psychedelic-assisted therapy and meditation training in the form of mindfulness-based interventions have been experimentally validated with moderate to large effects as alternative treatments for a variety of mental health problems, including depression, addictions, and anxiety disorders...
November 6, 2023: Pharmacological Reports: PR
https://read.qxmd.com/read/37891039/habit-reward-and-fear-related-motivations-in-alcohol-use-disorder-a-one-year-prospective-study
#22
JOURNAL ARTICLE
Marcelo Piquet-Pessôa, Joane de Oliveira, Ana Paula Ribeiro, Lucy Albertella, Gabriela M Ferreira, Gabriela B de Menezes, Leonardo F Fontenelle
OBJECTIVE: Cross-sectional studies show that habitual use of alcohol is associated with severity of alcohol dependence reflected across a range of domains and lower number of detoxifications in multiple settings. In this study, we investigated whether alcohol use disorder (AUD) patients with greater habitual use of alcohol at baseline showed worse outcomes after one year of follow-up. METHODS: A sample of inpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) alcohol use disorder (AUD) was assessed at baseline (n = 50) and after one year (n = 30)...
December 2023: Journal of Psychiatric Research
https://read.qxmd.com/read/37890539/input-output-relation-of-midbrain-connectomics-in-a-rodent-model-of-depression
#23
JOURNAL ARTICLE
Y Tong, S Cho, V A Coenen, M D Döbrössy
BACKGROUND: The symptoms associated with depression are believed to arise from disruptions in information processing across brain networks. The ventral tegmental area (VTA) influences reward-based behavior, motivation, addiction, and psychiatric disorders, including depression. Deep brain stimulation (DBS) of the medial forebrain bundle (MFB), is an emerging therapy for treatment-resistant depression. Understanding the depression associated anatomical networks crucial for comprehending its antidepressant effects...
October 25, 2023: Journal of Affective Disorders
https://read.qxmd.com/read/37880509/treatment-approaches-for-problematic-pornography-use-a-systematic-review
#24
JOURNAL ARTICLE
Thiago Henrique Roza, Lucas Tavares Noronha, Augusto Ossamu Shintani, Raffael Massuda, Maria Inês Rodrigues Lobato, Felix Henrique Paim Kessler, Ives Cavalcante Passos
Problematic pornography use (PPU) is an emerging condition associated with several negative psychological and sexual outcomes. This study aimed to systematically review treatment approaches for PPU. Potentially eligible studies were searched for in PubMed/MEDLINE, Embase, PsycINFO, and Web of Science up to April 1, 2023. The quality of the evidence was assessed with the use of the Joanna Briggs Institute's checklists, the Cochrane risk-of-bias tools, and the GRADE approach. A total of 8936 references were retrieved, and 28 studies were included in the systematic review (n = 500 participants)...
February 2024: Archives of Sexual Behavior
https://read.qxmd.com/read/37852214/involvement-of-plasma-melatonin-in-medication-overuse-headache-a-cross-sectional-study
#25
JOURNAL ARTICLE
Huimin Tao, Qi Wan, Mei Sun, Kefu Cai, Yan Song, Mingqing He, Jiabing Shen
OBJECTIVES: Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin in MOH compared with episodic migraine (EM) and healthy controls and to verify the relationship between plasma melatonin levels and psychiatric symptoms...
October 19, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37834235/antidepressant-medication-does-not-contribute-to-the-elevated-circulating-concentrations-of-acylethanolamides-found-in-substance-use-disorder-patients
#26
JOURNAL ARTICLE
Jesús Herrera-Imbroda, María Flores-López, Nerea Requena-Ocaña, Pedro Araos, Nuria García-Marchena, Jessica Ropero, Antonio Bordallo, Juan Suarez, Francisco J Pavón-Morón, Antonia Serrano, Fermín Mayoral, Fernando Rodríguez de Fonseca
Circulating acylethanolamides (NAEs) are bioactive signaling molecules that modulate multiple homeostatic functions including mood and hedonic responses. Variations in their plasma concentrations are associated with substance use disorders (SUD) and recent studies suggest that psychotropic medication might influence its circulating levels, limiting its use as a clinical biomarker of addiction. In addition, they might have a role as mediators of the pharmacological effects of psychotropic drugs. Thus, in mild depression, the response to selective serotonin reuptake inhibitor-type antidepressants (SSRI) is associated with a marked increase in circulating NAEs...
September 30, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37736438/mirtazapine-a-one-stop-strategy-for-treatment-of-opioid-withdrawal-symptoms
#27
REVIEW
Elisha Lalani, Raakhi Menon, Mariam A Mufti, Cecil Kumfa, Mukaila Raji
Public health efforts to reduce the opioid overdose epidemic and treat opioid use disorder (OUD) have met with challenges associated with current non-standardized approaches to managing opioid withdrawal symptoms, such as itching, jitteriness, anxiety, depression, craving, vomiting, diarrhea, insomnia, and anorexia. These symptoms pose substantial obstacles to the safe initiation of medications for OUD, maintenance of long-term sobriety, and prevention of relapse. In clinical practice, multiple medications (polypharmacy) are prescribed to manage these withdrawal symptoms, including ondansetron and promethazine for vomiting and nausea, loperamide and Lomotil for diarrhea, hydroxyzine and doxepin for pruritus, benzodiazepines, the Z-drugs, and melatonin for insomnia, and benzos, tricyclic antidepressants (TCAs), and various serotonergic agents for anxiety...
August 2023: Curēus
https://read.qxmd.com/read/37736170/psychoplastogens-a-novel-therapeutic-approach-for-neurological-diseases-and-disorders
#28
EDITORIAL
Robert B Kargbo
Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth and enhance neural structures, show promise in mitigating these changes. They activate key biological targets, including AMPA receptors, TrkB, and mTOR. Substances like ketamine, scopolamine, N , N -dimethyltryptamine, and rapastinel have psychoplastogenic properties. In clinical trials, psychedelic psychoplastogens have demonstrated antidepressant, anxiolytic, and anti-addictive effects...
September 14, 2023: ACS Medicinal Chemistry Letters
https://read.qxmd.com/read/37703770/potential-effect-of-antidepressants-on-remission-from-cocaine-use-disorder-a-nationwide-matched-retrospective-cohort-study
#29
JOURNAL ARTICLE
Zhenxiang Gao, T John Winhusen, Maria Gorenflo, Udi E Ghitza, Edward Nunes, Andrew J Saxon, Todd Korthuis, Kathleen Brady, Sean Luo, Pamela B Davis, David C Kaelber, Rong Xu
BACKGROUND: Cocaine use disorder (CUD) is a significant public health issue for which there is no Food and Drug Administration-approved pharmacotherapy. Depressive disorders are common psychiatric comorbidity amongst individuals with CUD. METHODS: A retrospective cohort study was conducted among 161,544 patients diagnosed with CUD and depression to evaluate the effectiveness of 13 antidepressants on CUD remission. For any antidepressant found to be associated with CUD remission that had an additional indication, we conducted an additional analysis to evaluate the effectiveness of the candidate drug in patients with CUD with that indication...
September 7, 2023: Drug and Alcohol Dependence
https://read.qxmd.com/read/37695876/adinazolam-a-benzodiazepine-type-new-psychoactive-substance-has-abuse-potential-and-induces-withdrawal-symptoms-in-rodents
#30
JOURNAL ARTICLE
Su-Bin Hwang, Jae-Gyeong Lee, Youyoung Lee, Wun-A Kook, Seon-Kyung Kim, Audrey Lynn Donio, Hee-Won Min, Young-Jung Kim, Seok-Yong Lee, Choon-Gon Jang
Adinazolam (ADZ) is a benzodiazepine-type new psychoactive substance (NPS) with anxiolytic, anticonvulsant, and antidepressant effects. High ADZ doses have been reported to impair psychomotor performance and memory; however, the abuse potential and drug dependence of ADZ have not yet been fully investigated. In this study, we evaluated whether ADZ has abuse potential and leads to drug dependence and withdrawal symptoms. The intravenous self-administration (IVSA) test revealed that ADZ (0.01, 0.03, and 0.1 mg/kg/infusion) was self-administered significantly above vehicle levels, suggesting the reinforcing effect of ADZ...
September 20, 2023: ACS Chemical Neuroscience
https://read.qxmd.com/read/37644342/the-toxicology-investigators-consortium-2022-annual-report
#31
JOURNAL ARTICLE
Alexandra M Amaducci, Sharan L Campleman, Shao Li, Dana L Karshenas, Meghan B Spyres, Lynn A Farrugia, A Min Kang, Rachel E Culbreth, Paul M Wax, Jeffrey Brent, Kim Aldy
Since 2010, medical toxicology physicians from the American College of Medical Toxicology (ACMT) Toxicology Investigators Consortium (ToxIC) have provided reports on their in-hospital and clinic patient consultations to a national case registry, known as the ToxIC Core Registry. De-identified patient data entered into the registry includes patient demographics, reason for medical toxicology evaluation, exposure agents, clinical signs and symptoms, treatments and antidotes administered, and mortality. This thirteenth annual report provides data from 7206 patients entered into the Core Registry in 2022 by 35 participating sites comprising 52 distinct healthcare facilities, bringing the total case count to 94,939...
October 2023: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://read.qxmd.com/read/37623151/consensus-panel-recommendations-for-the-pharmacological-management-of-pregnant-women-with-depressive-disorders
#32
REVIEW
Georgios Eleftheriou, Riccardo Zandonella Callegher, Raffaella Butera, Marco De Santis, Anna Franca Cavaliere, Sarah Vecchio, Alessandra Pistelli, Giovanna Mangili, Emi Bondi, Lorenzo Somaini, Mariapina Gallo, Matteo Balestrieri, Umberto Albert
INTRODUCTION: The initiative of a consensus on the topic of antidepressant and anxiolytic drug use in pregnancy is developing in an area of clinical uncertainty. Although many studies have been published in recent years, there is still a paucity of authoritative evidence-based indications useful for guiding the prescription of these drugs during pregnancy, and the data from the literature are complex and require expert judgment to draw clear conclusions. METHODS: For the elaboration of the consensus, we have involved the scientific societies of the sector, namely, the Italian Society of Toxicology, the Italian Society of Neuropsychopharmacology, the Italian Society of Psychiatry, the Italian Society of Obstetrics and Gynecology, the Italian Society of Drug Addiction and the Italian Society of Addiction Pathology...
August 11, 2023: International Journal of Environmental Research and Public Health
https://read.qxmd.com/read/37554454/polysubstance-addiction-patterns-among-7-989-individuals-with-cocaine-use-disorder
#33
JOURNAL ARTICLE
Brendan Stiltner, Robert H Pietrzak, Daniel S Tylee, Yaira Z Nunez, Keyrun Adhikari, Henry R Kranzler, Joel Gelernter, Renato Polimanti
To characterize polysubstance addiction (PSA) patterns of cocaine use disorder (CoUD), we performed a latent class analysis (LCA) in 7,989 participants with a lifetime DSM-5 diagnosis of CoUD. This analysis identified three PSA subgroups among CoUD participants (i.e., low, 17%; intermediate, 38%; high, 45%). While these subgroups varied by age, sex, and racial-ethnic distribution (p < 0.001), there was no difference with respect to education or income (p > 0.05). After accounting for sex, age, and race-ethnicity, the CoUD subgroup with high PSA had higher odds of antisocial personality disorder (OR = 21...
August 18, 2023: IScience
https://read.qxmd.com/read/37540344/gender-and-addiction-and-other-mental-disorders-comorbidity-sociodemographic-clinical-and-treatment-differences
#34
JOURNAL ARTICLE
Silvia Díaz Fernández, Juan José Fernandez Miranda, Francisco Pascual Pastor, Francisco López Muñoz
The co-occurrence of substance use disorders (SUD) and other mental disorders (OMD) is assumed to be high, but the details are uncertain in Spain. The objective of the present study was to know the prevalence of this comorbidity, as well as the pharmacological treatment, both in specific addiction treatment networks and in mental health networks, with a gender perspective. Observational, multicenter study, with a randomized sample, of patients under treatment for SUD or OMD in Spain (N = 1783). A specific questionnaire, collecting sociodemographic and clinical variables, diagnosed SUD and OMD, and prescribed psychotropic drugs, was completed by treating clinicians...
August 4, 2023: Archives of Women's Mental Health
https://read.qxmd.com/read/37536685/non-fatal-overdose-risk-associated-with-prescribing-opioid-agonists-concurrently-with-other-medication-cohort-study-conducted-using-linked-primary-care-secondary-care-and-mortality-records
#35
JOURNAL ARTICLE
Eleni Domzaridou, Matthew J Carr, Tim Millar, Roger T Webb, Darren M Ashcroft
BACKGROUND AND AIMS: An apparently protective effect of opioid agonist treatment (OAT) on all-cause and cause-specific mortality risk has been widely reported. Non-fatal overdose (NFO) often precedes subsequent drug-poisoning deaths. We hypothesized that benzodiazepines, gabapentinoids, antipsychotics, antidepressants, Z-drugs or opioids increase the NFO risk when co-prescribed with OAT. DESIGN: We conducted a cohort study using the Clinical Practice Research Datalink GOLD and Aurum databases...
December 2023: Addiction
https://read.qxmd.com/read/37513925/exploring-the-molecular-targets-for-the-antidepressant-and-antisuicidal-effects-of-ketamine-enantiomers-by-using-network-pharmacology-and-molecular-docking
#36
JOURNAL ARTICLE
Glorister A Altê, Ana Lúcia S Rodrigues
Ketamine, a racemic mixture of esketamine (S-ketamine) and arketamine (R-ketamine), has received particular attention for its rapid antidepressant and antisuicidal effects. NMDA receptor inhibition has been indicated as one of the main mechanisms of action of the racemic mixture, but other pharmacological targets have also been proposed. This study aimed to explore the possible multiple targets of ketamine enantiomers related to their antidepressant and antisuicidal effects. To this end, targets were predicted using Swiss Target Prediction software for each ketamine enantiomer...
July 17, 2023: Pharmaceuticals
https://read.qxmd.com/read/37500482/efficacy-and-safety-of-antidepressants-for-smoking-cessation-a-systematic-review-and-network-meta-analysis
#37
REVIEW
Xinxin Deng, Xue Shang, Kangle Guo, Liying Zhou, Yongsheng Wang, Yanan Wu, Shanshan Liang, Fenfen E, Wendi Liu, Ziyi Wang, Xiuxia Li, Kehu Yang
To evaluate the effectiveness, safety and tolerability of antidepressants in helping smokers quit tobacco dependence, five databases were searched for randomized controlled trials (RCTS ) on different antidepressant interventions involving smoking cessation in populations (September 2022). The STATA 15.1 software was used to perform network meta-analysis. The Cochrane bias risk tool was used to assess the risk of bias, and CINeMA was used to evaluate the evidence credibility for the effect of different interventions on smoking cessation...
August 2023: Addiction Biology
https://read.qxmd.com/read/37458668/psychological-effects-of-the-covid-19-pandemic-what-do-we-know-about-them
#38
JOURNAL ARTICLE
M Glinianowicz, D Ciura, E Burnatowska, M Olszanecka-Glinianowicz
The coronavirus disease 2019 (COVID-19) pandemic was a shock to the whole world. This pandemic caused not only many deaths of people of all ages and health effects that are still difficult to assess, but also economic, and psychological ones. Numerous studies have shown that chronic stress related to social isolation and fear of contagion increased the rates of development of anxiety, depression syndrome, emotional eating, and posttraumatic stress disorder (PTSD). The increased rate of substance use and antidepressant drugs has also been observed...
July 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37453197/the-synergistic-mechanism-of-action-of-dajianzhong-decoction-in-conjunction-with-ketamine-in-the-treatment-of-depression
#39
JOURNAL ARTICLE
Chan Li, Jiping Zhang, Hanhe Liu, Huijie Yuan, Jianxin Cai, Manoela V Fogaça, Yuan-Wei Zhang
Depression is a multifactorial syndrome with a variety of underlying pathological mechanisms. While ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits a rapid antidepressant action in the central never system (CNS), the potential addiction and psychotomimetic adverse effects of ketamine limit its chronic use in clinical practice. Therefore, it is necessary to discover an additional agent that shows a synergistic antidepressant activity with ketamine to sustain its therapeutic action so as to reduce its use frequency in depression treatment...
July 13, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37446323/treatment-resistant-depression-trd-is-the-opioid-system-involved
#40
JOURNAL ARTICLE
Shaul Schreiber, Lee Keidan, Chaim G Pick
About 30% of major depression disorder patients fail to achieve remission, hence being diagnosed with treatment-resistant major depression (TRD). Opium had been largely used effectively to treat depression for centuries, but when other medications were introduced, its use was discounted due to addiction and other hazards. In a series of previous studies, we evaluated the antinociceptive effects of eight antidepressant medications and their interaction with the opioid system. Mice were tested with a hotplate or tail-flick after being injected with different doses of mianserin, mirtazapine, trazodone, venlafaxine, reboxetine, moclobemide, fluoxetine, or fluvoxamine to determine the effect of each drug in eliciting antinociception...
July 6, 2023: International Journal of Molecular Sciences
keyword
keyword
18637
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.